Top Markets
#1 ADO Protocol ADO Protocol +193.12%
#2 Islamic Coin Islamic Coin +155.43%
#3 GoPlus Security GoPlus Security +48.69%
#4 GAIB AID GAIB AID +24.67%
#5 Starpower Starpower +17.54%
#6 Chia Chia +15.11%
#7 Casper Network Casper Network +13.73%
#8 Verus Coin Verus Coin +13.56%
#9 o1.exchange o1.exchange +12.82%
#10 Pons Pons +12.26%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Classifica tra le azioni #33575
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Prezzo delle azioni
$0.07828624
Capitalizzazione di mercato
$7.37M
Variazione (1 giorno)
3.13%
Variazione (1 anno)
-39.20%
Paese
DE
Scambia TME Pharma N.V. (ALTME)

Categoria

Healthcare
Rapporto P/S per TME Pharma N.V. (ALTME)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di TME Pharma N.V., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per TME Pharma N.V. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE